 
        
        
         
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | Opioid receptor ↓ ↑ | ORL1 ↓ ↑ | μ-opioid receptor ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Racecadotril | ✔ | 98% | |||||||||||||||||
| JTC-801 | ++ Opioid receptor-like1 (ORL1), IC50: 94 nM | 98% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | PZM21 is a potent and selective μ opioid receptor agonist with an EC50 of 1.8 nM. | 
| Concentration | Treated Time | Description | References | |
| LAD2 human mast cells | 0.1 to 10 µM | 2 hours | Evaluate the effect of PZM21 on mast cell degranulation; results showed no significant effect | Anesthesiology. 2019 Jul;131(1):132-147 | 
| HEK 293 cells | 1- 30000 nM | 2 minutes (Gi activation) and 10 minutes (arrestin-3 translocation) | Measure the effects of PZM21 on Gi protein activation and arrestin-3 translocation in HEK 293 cells. Results showed PZM21 is a low efficacy agonist for both Gi activation and arrestin-3 translocation. | Br J Pharmacol. 2018 Jul;175(13):2653-2661 | 
| Mouse Embryonic Fibroblasts (MEFs) | 0.03 to 30 µM | 48 hours | Evaluate the effect of PZM21 on fibroblast proliferation; results showed no significant effect | Anesthesiology. 2019 Jul;131(1):132-147 | 
| Administration | Dosage | Frequency | Description | References | ||
| Rhesus macaques | Acute thermal nociception and drug self-administration model | Subcutaneous and intrathecal | 1.0-6.0 mg/kg (subcutaneous), 0.03-0.3 mg (intrathecal) | Single administration, observed for 5 hours | To evaluate the antinociceptive effects, drug self-administration behavior, and pruritic effects of PZM21. Results showed PZM21 had similar antinociceptive effects and abuse potential as oxycodone, and intrathecal administration induced significant itch scratching. | Br J Anaesth. 2020 Oct;125(4):596-604 | 
| Mice | C57BL/6J mice | Subcutaneous injection | 10 mg/kg, 20 mg/kg, 40 mg/kg | Single administration | PZM21 displayed dose-dependent analgesia in a mouse hotplate assay, with a per cent maximal possible effect (% MPE) of 87% reached 15 min after administration of the highest dose of drug tested (40 mg/kg). The highest dose of morphine tested plateaued at 92% after 30 min. Intriguingly, no analgesic effect was observed for PZM21 in the tail-flick assay. PZM21 solely confers analgesia to the affective component of pain, with minimal effect on the reflexive component. Additionally, PZM21 was devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses. | Nature. 2016 Sep 8;537(7619):185-190 | 
| Mice (C57BL and CD-1) | Awake, freely moving mice | Intraperitoneal (i.p.) and subcutaneous (s.c.) injection | 10–80 mg/kg | Single dose or twice daily administration for 3-5 days | Evaluate the effects of PZM21 on respiration and antinociception. Results showed PZM21 dose-dependently depressed respiration, similar to morphine. Repeated administration induced tolerance to antinociception but not to respiratory depression. | Br J Pharmacol. 2018 Jul;175(13):2653-2661 | 
| CD-1 mice | Acetic acid-induced writhing model, hot-water tail withdrawal test, formalin-induced paw licking assay | Intravenous injection | 20 mg/kg (intravenous injection) | Single dose | Evaluate the analgesic effects of the compounds. Results showed that compounds 6a, 6f, 6h, and 6k exhibited analgesia rates exceeding 97% in the acetic acid-induced writhing model, compounds 6a, 6b, and 6h showed significant antinociceptive action in the hot-water tail withdrawal test, and compounds 6a, 6f, and 6h exhibited prolonged antinociceptive effects in the formalin-induced paw licking assay | Molecules. 2024 Jun 21;29(13):2961 | 
| ICR mice | Formalin injection nociception assay and writhing test | Subcutaneous injection | 20 mg/kg and 40 mg/kg (formalin injection assay), 10 mg/kg (writhing test) | Single dose | To evaluate the analgesic effects of PZM21 and its analogues, PZM21 showed 77.9% and 92.8% analgesia in the formalin injection assay at 20 mg/kg and 40 mg/kg, respectively. | Molecules. 2019 Jan 11;24(2):259 | 
| Mice and rats | Thermal antinociception tests, conditioned place preference test, locomotor sensitization test, precipitated withdrawal test, self-administration test | Intraperitoneal or intrathecal | 20, 40, or 80 mg/kg (i.p.); 2.5, 5, or 7.5 μg (intrathecal) | Single or repeated administration, lasting from hours to days | PZM21 exhibited antinociceptive efficacy, without rewarding or reinforcing properties. However, repeated administration led to antinociceptive tolerance and naloxone-precipitated withdrawal symptoms. PZM21 also enhanced morphine-induced antinociception and attenuated the expression of morphine reward. | Br J Pharmacol. 2019 Dec;176(23):4434-4445 | 
| Adult male Hartley guinea pigs | Lumbar intrathecal catheter connected to osmotic pump model | Intrathecal infusion | 28 nmol/hour | Continuous for 14 days | Evaluate the effect of PZM21 on spinal mass formation in vivo; results showed no mass formation | Anesthesiology. 2019 Jul;131(1):132-147 | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.77mL 0.55mL 0.28mL | 13.83mL 2.77mL 1.38mL | 27.66mL 5.53mL 2.77mL | |
| CAS号 | 1997387-43-5 | 
| 分子式 | C19H27N3O2S | 
| 分子量 | 361.5 | 
| SMILES Code | O=C(N[C@@H](C)CC1=CSC=C1)NC[C@@H](N(C)C)CC2=CC=C(O)C=C2 | 
| MDL No. | MFCD30802176 | 
| 别名 | |
| 运输 | 蓝冰 | 
| InChI Key | MEDBIJOVZJEMBI-YOEHRIQHSA-N | 
| Pubchem ID | 121596705 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, 2-8°C | 
| 溶解方案 | DMSO: 105 mg/mL(290.46 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1